TISIDB

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF05965 F/Y rich C-terminus PF05964 F/Y-rich N-terminus PF00628 PHD-finger PF00856 SET domain PF02008 CXXC zinc finger domain
Function	Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in beta-globin locus transcription regulation by being recruited by NFE2. Plays an important role in controlling bulk H3K4me during oocyte growth and preimplantation development. Required during the transcriptionally active period of oocyte growth for the establishment and/or maintenance of bulk H3K4 trimethylation (H3K4me3), global transcriptional silencing that preceeds resumption of meiosis, oocyte survival and normal zygotic genome activation.

> Gene Ontology [ TOP ]
Biological Process	GO:0001541 ovarian follicle development GO:0006338 chromatin remodeling GO:0006479 protein methylation GO:0007281 germ cell development GO:0007292 female gamete generation GO:0007548 sex differentiation GO:0007611 learning or memory GO:0007613 memory GO:0008213 protein alkylation GO:0008406 gonad development GO:0008585 female gonad development GO:0009994 oocyte differentiation GO:0016458 gene silencing GO:0016570 histone modification GO:0016571 histone methylation GO:0018022 peptidyl-lysine methylation GO:0018023 peptidyl-lysine trimethylation GO:0018205 peptidyl-lysine modification GO:0022412 cellular process involved in reproduction in multicellular organism GO:0022602 ovulation cycle process GO:0030728 ovulation GO:0031056 regulation of histone modification GO:0031060 regulation of histone methylation GO:0032259 methylation GO:0034968 histone lysine methylation GO:0040029 regulation of gene expression, epigenetic GO:0042698 ovulation cycle GO:0043414 macromolecule methylation GO:0044708 single-organism behavior GO:0045137 development of primary sexual characteristics GO:0045815 positive regulation of gene expression, epigenetic GO:0046545 development of primary female sexual characteristics GO:0046660 female sex differentiation GO:0048096 chromatin-mediated maintenance of transcription GO:0048477 oogenesis GO:0048511 rhythmic process GO:0048608 reproductive structure development GO:0050890 cognition GO:0051568 histone H3-K4 methylation GO:0051569 regulation of histone H3-K4 methylation GO:0061458 reproductive system development GO:0080182 histone H3-K4 trimethylation GO:1902275 regulation of chromatin organization
Molecular Function	GO:0008168 methyltransferase activity GO:0008170 N-methyltransferase activity GO:0008276 protein methyltransferase activity GO:0008757 S-adenosylmethionine-dependent methyltransferase activity GO:0016278 lysine N-methyltransferase activity GO:0016279 protein-lysine N-methyltransferase activity GO:0016741 transferase activity, transferring one-carbon groups GO:0018024 histone-lysine N-methyltransferase activity GO:0042054 histone methyltransferase activity GO:0042800 histone methyltransferase activity (H3-K4 specific)
Cellular Component	GO:0034708 methyltransferase complex GO:0035097 histone methyltransferase complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00310 Lysine degradation
Reactome	R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-3214841: PKMTs methylate histone lysines

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KMT2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KMT2B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: 1.82; FDR: 0.000381	Sensitive to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KMT2B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.056	0.784
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.195	0.895
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.045	0.968
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.172	0.61
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.258	0.926
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.068	0.985
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.286	0.37
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.298	0.839
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.278	0.865
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.428	0.506
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.88	0.299
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.084	0.21

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KMT2B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	5.9	17.9	0.197
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	9.1	21.7	0.327
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	11.1	-8.5	0.299
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	15.4	-10.9	0.541
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KMT2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KMT2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KMT2B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KMT2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KMT2B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KMT2B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KMT2B
Name	lysine (K)-specific methyltransferase 2B
Aliases	KIAA0304; HRX2; WBP7; MLL1B; CXXC10; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophi ......
Chromosomal Location	19q13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KMT2B collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KMT2B